Pfizer is going to fight to keep doctors from switching to generic simvastatin. In the majority of cases, simvastatin will do just fine.
Pfizer is going to fight to keep doctors from switching to generic simvastatin
ADVERTISEMENT
Related Posts
More in Uncategorized
Past Week
-
The conflict of interest that discloses as nothing
-
Blood sugar and brain aging start long before diabetes
-
Private equity in medicine did not kill private practice
-
Setting boundaries as a physician doesn’t mean caring less
-
Medicare home care coverage pays for rehab, not an aide
-
Automation bias in health care can become paternalism
-
Past 6 Months
-
Why CDC opioid guidelines get the overdose data wrong
-
Retirement isn’t the end of medicine, it’s a second act [PODCAST]
-
Sensory processing in autism and the brain’s volume control
-
What maternity care deserts cost a town
-
Why medicine needs a national physician license now
-
A cold cost $945. The cost of primary care is broken.
-
Recent Posts
-
Blood sugar and brain aging start long before diabetes
-
What did the tirzepatide study actually test?
-
Why is psychic pain treated as a symptom instead of pain?
-
Diagnostic overshadowing and the war in her throat
-
Why do charity commercials leave clinicians uneasy?
-
Revenue cycle management is more than medical billing
-
Subscribe to KevinMD and never miss a story!
Get free updates delivered free to your inbox.
